The Novartis Malaria Initiative

Primary tabs

The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity building, the initiative is the largest access-to-medicine program within Novartis measured by the number of patients reached annually. Together with our partners, and with our continued patient-centric approach, we are committed to the common goal of malaria elimination.

Content from this campaign

Novel Novartis Compound Shows Potential as Effective Therapy for Treating Drug Resistant Malaria
Results published in the New England Journal of Medicine demonstrate thatKAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites KAF156, currently in phase IIb, is the first compound from a novel class of antimalarials known as imidazolopiperazines Antimalarials...
Sep 21, 2016 5:00 PM ET
At a Juncture in Malaria Eradication
We are at a juncture in malaria eradication. If we can sustain the extraordinary efforts of the past 15 years and continue to invest much needed resources, we stand a chance of reaching a malaria-free world within our generation. The upcoming fifth Replenishment Conference of the Global Fund to Fight AIDS, Tuberculosis and Malaria in Canada represents an important milestone in the fight...
Sep 15, 2016 9:35 AM ET
Malaria Experts and African Leaders Challenged to Maintain the Momentum and Win the Race for Malaria Elimination
National Malaria Control Program best practice sharing workshop takes place in Senegal, which has made great strides in malaria control  Event brings together delegates from 33 African countries to accelerate malaria elimination efforts   Novartis Malaria Initiative celebrates treatment delivery milestone, with more than 800 million...
Jul 13, 2016 1:15 AM ET
Preparing to Stop Drug-Resistant Malaria
No child should ever die from a mosquito bite. Yet, today, in an era of extraordinary medical advancement, a child dies of mosquito-borne malaria every two minutes. Last year, this agonizing blood disease caused by the malaria parasite claimed nearly half a million lives—most of them children. Still, there’s unprecedented cause for optimism. After 15 years of coordinated efforts to...
Jun 23, 2016 3:20 AM ET
Novartis Expands Partnership with Medicines for Malaria Venture to Develop Next-Generation Antimalarial Treatment
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment  Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation KAF156 belongs...
Jun 15, 2016 11:20 AM ET